| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
To investigate prognostic markers for conversion from MCI to dementia, we have focused on patients with late-life depression (LLD) who are at high risk of dementia. Higher plasma Aβ40 was associated with higher degree of parahippocampal atrophy and lower verbal fluency performance. The LLD patients were divided into 3 groups according to their cognitive status before and after the treatment, i.e., (i) cognitively normal subjects, (ii) the MCI reverters to normal cognition, and (iii) MCI-non-reverters. Remarkably, we found higher plasma Aβ40 levels and lower verbal fluency performance at baseline in the MCI-non-reverters who were at highest risk of dementia compared with the other 2 groups. Because these alterations were not significantly found in amnestic MCI without depression, plasma Aβ40 and verbal fluency performance may function as prognostic markers for conversion from MCI to dementia specifically in LLD patients. Serum oxidized RNA did not function as a prognostic marker.
|
